Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies By Hans Constandt From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the… Read More
Gene Editing: Re-writing Genomes With Targetable Nucleases By Dr Dana Carroll We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed… Read More
Automated Compound Management Evolves To Meet The Drug Discovery Demands Of The Future By Dr Caroline Engeloch and Dr Daniel Baeschlin The development of new drugs involves testing hundreds of thousands of compounds, from high throughput screening through to subsequent lead optimization. Recognizing the importance of a compound bank in… Read More
Fluorescence Lifetime Assays By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen The benefits of fluorescence lifetime-based technologies (FLT) have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance. Significant improvements in assay reagents and availability of… Read More
By Dr Alejandra Solache, Robert Brockett, Trinette Chuang, Dr Robin Clark, Rey Dimagiba, Dr April Fisher, Dr Wayne Speckmann and Dr Chun Yang Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting… Read More
Partnering with the right CRO is a winning strategy for companies big and small By Dr Davide Molho The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen the biopharmaceutical industry gradually become more willing to look externally and embrace the concept of outsourcing… Read More
Highlights from GlobalData’s CRO Benchmark Report By Adam M. Dion The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing sleep at night. Read More
Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More
Unrevealing Biological Secrets By Single Cell Expression Profiling By Dr Mikael Kubista and Dr Anders Ståhlberg During the last 30 years exceedingly sensitive and accurate technologies have been developed to measure and quantify amounts of nucleic acids and proteins. With techniques such as quantitative real-time PCR (qPCR) and nextgeneration sequencing… Read More
A Decade of RNAi Screening: Too much hay and very few needles By Bhavneet Bhinder and Dr Hakim Djaballah RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics wave, and in… Read More
Stem Cells Rapidly Gaining Traction in Research and Drug Discovery By Dr John Comley A recent market survey on stem cells in research and drug discovery showed that despite a significant amount of hype and hope around stem cells, most drug discovery-related efforts today still fall into the category of… Read More
Targeting Diminished Cerebral Glucose Metabolism for Alzheimer’s Disease By Dr Henderson As demographics of developed countries shift toward an older population, the number of cases of Alzheimer’s disease is anticipated to increase dramatically. Currently, there are no disease modifying treatments and approved drugs provide only symptomatic relief. Amyloid beta has… Read More
Multi-Parameter Flow Cytometry Technology Advances for Rare Cell Analysis and Sorting By David Gebhard and Dr Diether Recktenwald The study of rare cell populations is important to advance medical diagnostics and therapeutics. For many clinical studies, rare cell counts promise to provide valuable alternate end points; examples are circulating tumour… Read More
There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Such diseases usually have a genetic basis, often… Read More
Realising The Genome's Potential In The Context Of The Living Cell By Dr Amr Abid A decade ago, with the completion of the Human Genome Project (HGP), scientists had the long-awaited sequence of the human genome in hand. Once decoded, this invaluable source of data was anticipated to reveal the… Read More
Adoption Of High Content Screening At High Throughput Screening Laboratories By William Downey and Dr Jennifer Hartigan Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays and high content screening… Read More